GeoVax Labs, Inc. (NASDAQ:GOVX) Director Purchases $12,100.00 in Stock

GeoVax Labs, Inc. (NASDAQ:GOVXGet Rating) Director Randal D. Chase purchased 10,000 shares of GeoVax Labs stock in a transaction dated Tuesday, June 21st. The shares were acquired at an average cost of $1.21 per share, for a total transaction of $12,100.00. Following the completion of the transaction, the director now owns 26,613 shares of the company’s stock, valued at approximately $32,201.73. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of GOVX stock opened at $1.25 on Wednesday. The business’s fifty day simple moving average is $1.22 and its 200-day simple moving average is $1.98. GeoVax Labs, Inc. has a 12-month low of $0.55 and a 12-month high of $7.50.

GeoVax Labs (NASDAQ:GOVXGet Rating) last issued its quarterly earnings results on Wednesday, April 27th. The company reported ($0.34) earnings per share (EPS) for the quarter. The business had revenue of $0.08 million for the quarter. GeoVax Labs had a negative return on equity of 146.19% and a negative net margin of 5,443.98%.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GOVX. Susquehanna International Group LLP acquired a new position in shares of GeoVax Labs in the 4th quarter valued at $42,000. Two Sigma Securities LLC acquired a new position in shares of GeoVax Labs in the 3rd quarter valued at $49,000. Squarepoint Ops LLC acquired a new position in shares of GeoVax Labs in the 3rd quarter valued at $51,000. Virtu Financial LLC acquired a new position in shares of GeoVax Labs in the 1st quarter valued at $57,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of GeoVax Labs in the 4th quarter valued at $100,000. 6.53% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Maxim Group reaffirmed a “buy” rating and set a $6.00 price target on shares of GeoVax Labs in a research report on Monday, May 23rd.

About GeoVax Labs (Get Rating)

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for GeoVax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeoVax Labs and related companies with MarketBeat.com's FREE daily email newsletter.